Amgen and Advaxis agree $40m cancer treatment deal

10-08-2016

Amgen and Advaxis agree $40m cancer treatment deal

Incomible / Shutterstock.com

Amgen has entered into a global agreement with Advaxis, allowing for the development and commercialisation of ADXS-NEO, a preclinical cancer immunotherapy treatment.


Amgen, Advaxis, ADXS-NEO, cancer treatment

LSIPR